{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "K",
          "alt": "A",
          "position": "48"
        },
        "variant_string_id": "parkin K48A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper describes the effects of causative mutations within the ubiquitin-like domain in autosomal recessive juvenile Parkinson’s disease.",
          "judgment": "Yes",
          "reasoning": "The text mentions that point mutations in parkin, an E3 ligase involved in ubiquitination pathway, are one of the most commonly observed traits in autosomal recessive juvenile Parkinson’s disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses a urea unfolding experiment to determine stability of parkin Ubld and ubiquitin, providing structural and folding insight into the effects of causative mutations.",
          "judgment": "Yes",
          "reasoning": "Urea unfolding experiments are commonly used in studies of protein structure and stability, particularly when examining mutations that may affect these properties. The paper specifically states that the goal is to provide insight into the effects of causative mutations, aligning with the general aim of modeling or reflecting disease pathogenesis/mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "sub_step_name": "3a. Basic Controls and Replicates",
              "sub_questions": [
                {
                  "question": "Were basic controls included?",
                  "answer": "Yes"
                },
                {
                  "question": "Did the paper explicitly state that multiple replicates were used?",
                  "answer": "No, but the results are presented as means ± standard deviations, suggesting repetition."
                }
              ],
              "judgment": "The assay includes basic controls (wild-type and null control) but does not explicitly state multiple replicates were used in this specific instance of the assay."
            },
            {
              "sub_step_name": "3b. Accepted/Validated Assay",
              "question": "Has the specific instance of the assay been: a) Broadly accepted historically? OR b) Previously validated in other studies? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
              "answer": "The assay is not described as a standard technique or previously validated."
            },
            {
              "sub_step_name": "3c. Variant Controls",
              "question": "Were variant controls used in the assay for this variant?",
              "answer": "No, no specific pathogenic or benign variants were used as controls."
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "sub_step_name": "4a. Statistical Analyses",
              "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
              "answer": "No, no direct calculation or reporting of OddsPath is provided."
            },
            {
              "sub_step_name": "4b. No OddsPath Calculation",
              "question": "How many total benign/pathogenic variant controls were used across the entire study?",
              "answer": "The paper does not provide a total count of benign and pathogenic control variants used in all assays."
            }
          ]
        }
      ],
      "functional_evidence_strength": "Max PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "",
          "alt": "A",
          "position": "Not provided"
        },
        "variant_string_id": "parkin A (Not provided)"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper describes the effects of causative mutations within the ubiquitin-like domain in autosomal recessive juvenile Parkinson’s disease.",
          "judgment": "Yes",
          "reasoning": "The text mentions that point mutations in parkin, an E3 ligase involved in ubiquitination pathway, are one of the most commonly observed traits in autosomal recessive juvenile Parkinson’s disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses a protein interaction assay to examine the effects of causative mutations on parkin’s ability to interact with other proteins.",
          "judgment": "Yes",
          "reasoning": "Protein interaction assays are commonly used in studies of protein function, particularly when examining mutations that may affect protein interactions. The paper specifically states that the goal is to examine the effects of causative mutations on parkin’s ability to interact with other proteins, aligning with the general aim of modeling or reflecting disease pathogenesis/mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "sub_step_name": "3a. Basic Controls and Replicates",
              "sub_questions": [
                {
                  "question": "Were basic controls included?",
                  "answer": "Yes"
                },
                {
                  "question": "Did the paper explicitly state that multiple replicates were used?",
                  "answer": "No, but the results are presented as means ± standard deviations, suggesting repetition."
                }
              ],
              "judgment": "The assay includes basic controls (wild-type and empty vector) but does not explicitly state multiple replicates were used in this specific instance of the assay."
            },
            {
              "sub_step_name": "3b. Accepted/Validated Assay",
              "question": "Has the specific instance of the assay been: a) Broadly accepted historically? OR b) Previously validated in other studies? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
              "answer": "The assay is not described as a standard technique or previously validated."
            },
            {
              "sub_step_name": "3c. Variant Controls",
              "question": "Were variant controls used in the assay for this variant?",
              "answer": "No, no specific pathogenic or benign variants were used as controls."
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "sub_step_name": "4a. Statistical Analyses",
              "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
              "answer": "No, no direct calculation or reporting of OddsPath is provided."
            },
            {
              "sub_step_name": "4b. No OddsPath Calculation",
              "question": "How many total benign/pathogenic variant controls were used across the entire study?",
              "answer": "The paper does not provide a total count of benign and pathogenic control variants used in all assays."
            }
          ]
        }
      ],
      "functional_evidence_strength": "Max PS3_supporting"
    }
  ]
}